NASDAQ: TCRX
TScan Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$46.68M
52w High
$2.57
52w Low
$0.72
P/E
-0.84
Volume
222.76K
Outstanding Shares
61.07M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 57.81% over the last year. Revenue grew 2.15% over the trailing twelve months. Operating margin moved from -2,072.07% to -1,695.15%. Free cash flow grew 9.76% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -1,695.15%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q4 FY26 · EPS est -$0.28 · Revenue est $1.45M
View